Deals Shaping The Medical Industry (03/2012)
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
You may also be interested in...
Line extension for physician’s brand BrainMD intends to support secretion of glucagon-like peptide-1; research shows AllerPops prebiotic lozenges improved rhinitis allergy symptoms significantly; and Nutramax Laboratories developing Practitioner Formulas supplements with health care professionals.
Under CEO Erik Fyrwald, IFF is committed to improving commercial execution across its four businesses after five years of overall underperformance.
Analysts had forecast Q4 Roctavian sales of $5m-$6m, but they came in shy of $3m, and uptake has not yet come to reflect apparent demand.